Literature DB >> 21036512

Unintended pregnancy in opioid-abusing women.

Sarah H Heil1, Hendree E Jones, Amelia Arria, Karol Kaltenbach, Mara Coyle, Gabriele Fischer, Susan Stine, Peter Selby, Peter R Martin.   

Abstract

The aim of this study was to estimate the prevalence of unintended pregnancy and its three subtypes (mistimed, unwanted, and ambivalent) among opioid-abusing women. In the general population, 31%-47% of pregnancies are unintended; data on unintended pregnancy in opioid- and other drug-abusing women are lacking. Pregnant opioid-abusing women (N = 946) screened for possible enrollment in a multisite randomized controlled trial comparing opioid maintenance medications completed a standardized interview assessing sociodemographic characteristics, current and past drug use, and pregnancy intention. Almost 9 of every 10 pregnancies were unintended (86%), with comparable percentages mistimed (34%), unwanted (27%), and ambivalent (26%). Irrespective of pregnancy intention, more than 90% of the total sample had a history of drug abuse treatment, averaging more than three treatment episodes. Interventions are sorely needed to address the extremely high rate of unintended pregnancy among opioid-abusing women. Drug treatment programs are likely to be an important setting for such interventions.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21036512      PMCID: PMC3052960          DOI: 10.1016/j.jsat.2010.08.011

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  8 in total

Review 1.  Women and smoking: understanding socioeconomic influences.

Authors:  Hilary Graham
Journal:  Drug Alcohol Depend       Date:  2009-04-03       Impact factor: 4.492

Review 2.  Opioid dependence during pregnancy. Effects and management.

Authors:  K Kaltenbach; V Berghella; L Finnegan
Journal:  Obstet Gynecol Clin North Am       Date:  1998-03       Impact factor: 2.844

3.  Pregnancy intention and its relationship to birth and maternal outcomes.

Authors:  A P Mohllajee; K M Curtis; B Morrow; P A Marchbanks
Journal:  Obstet Gynecol       Date:  2007-03       Impact factor: 7.661

4.  Differences between mistimed and unwanted pregnancies among women who have live births.

Authors:  Denise V D'Angelo; Brenda Colley Gilbert; Roger W Rochat; John S Santelli; Joan M Herold
Journal:  Perspect Sex Reprod Health       Date:  2004 Sep-Oct

5.  Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth.

Authors:  Anjani Chandra; Gladys M Martinez; William D Mosher; Joyce C Abma; Jo Jones
Journal:  Vital Health Stat 23       Date:  2005-12

6.  Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users.

Authors:  P A Selwyn; R J Carter; E E Schoenbaum; V J Robertson; R S Klein; M F Rogers
Journal:  JAMA       Date:  1989 Jun 23-30       Impact factor: 56.272

7.  Reproductive health needs: comparing women at high, drug-related risk of HIV with a national sample.

Authors:  K A Armstrong; M G Kennedy; A Kline; C Tunstall
Journal:  J Am Med Womens Assoc (1972)       Date:  1999

Review 8.  Treatment of opioid-dependent pregnant women: clinical and research issues.

Authors:  Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer
Journal:  J Subst Abuse Treat       Date:  2008-01-14
  8 in total
  61 in total

1.  Knowledge of and concerns about long-acting reversible contraception among women in medication-assisted treatment for opioid use disorder.

Authors:  Alexis K Matusiewicz; Heidi S Melbostad; Sarah H Heil
Journal:  Contraception       Date:  2017-08-02       Impact factor: 3.375

2.  Increasing pregnancy-related use of prescribed opioid analgesics.

Authors:  Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper
Journal:  Ann Epidemiol       Date:  2013-08       Impact factor: 3.797

Review 3.  Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.

Authors:  Mishka Terplan; Dennis J Hand; Melissa Hutchinson; Elizabeth Salisbury-Afshar; Sarah H Heil
Journal:  Prev Med       Date:  2015-04-18       Impact factor: 4.018

4.  Safety of the newer class of opioid antagonists in pregnancy.

Authors:  Shirley Poon; Anna Pupco; Gideon Koren; Pina Bozzo
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

5.  Intendedness of pregnancy and other predictive factors for symptoms of prenatal depression in a population-based study.

Authors:  Jena L Fellenzer; Donald A Cibula
Journal:  Matern Child Health J       Date:  2014-12

Review 6.  Adolescent substance use and unplanned pregnancy: strategies for risk reduction.

Authors:  Hilary Smith Connery; Brittany B Albright; John M Rodolico
Journal:  Obstet Gynecol Clin North Am       Date:  2014-04-06       Impact factor: 2.844

Review 7.  A Dissemination and Implementation Science Approach to the Epidemic of Opioid Use Disorder in the United States.

Authors:  Stephanie M Mathis; Nicholas Hagemeier; Angela Hagaman; John Dreyzehner; Robert P Pack
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

8.  Expanding Contraception Access for Women With Opioid-Use Disorder: A Qualitative Study of Opportunities and Challenges.

Authors:  Emily A Hurley; Alex Duello; Sarah Finocchario-Kessler; Kathy Goggin; Stephani Stancil; Rachel P Winograd; Melissa K Miller
Journal:  Am J Health Promot       Date:  2020-05-29

9.  Editorial: 2nd Special Issue on behavior change, health, and health disparities.

Authors:  Stephen T Higgins
Journal:  Prev Med       Date:  2015-08-06       Impact factor: 4.018

10.  Using behavioral economic theory to increase use of effective contraceptives among opioid-maintained women at risk of unintended pregnancy.

Authors:  Sarah H Heil; Dennis J Hand; Stacey C Sigmon; Gary J Badger; Marjorie C Meyer; Stephen T Higgins
Journal:  Prev Med       Date:  2016-06-23       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.